Company news
Brightgene Bio-medical Technology Co. Ltd. Class A (SSE:688166) news
Brightgene Bio-medical Technology Co. Ltd. Class A news releases on 6ix. Latest, Sep 18, 2026: "BrightGene Bio-Medical Technology Co., Ltd."Announcement…
Press releases & updates
"BrightGene Bio-Medical Technology Co., Ltd."Announcement on Results of Shareholding Reduction by Shareholder
September 17, 2026
"BrightGene Bio-Medical Technology Co., Ltd."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 8, 2026
"BrightGene Bio-Medical Technology Co., Ltd."Semi-annual Report for 2026
August 30, 2026
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on Voluntary Disclosure of the Phase I Clinical Trial Data of BGM1812 Injection for Weight Loss Indication
August 6, 2026
"Brightgene Bio-Medical Technology Co., Ltd."Voluntary Disclosure Announcement on Acquisition of Drug Registration Certificate for Tiotropium Bromide Inhalation Spray by a Controlled Subsidiary
July 31, 2026
"Brightgene Bio-Medical Technology Co., Ltd."Voluntary Disclosure Announcement on Acquisition of Drug Registration Certificate for Tiotropium Bromide and Olodaterol Inhalation Spray by a Controlled Subsidiary
July 24, 2026
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on the Board Secretary's Obtaining the Certificate of Qualification Training and Officially Assuming Duties
July 23, 2026
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on Appointment of Secretary of the Board of Directors
July 20, 2026
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
July 17, 2026
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
July 16, 2026
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
July 10, 2026
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on Serious Abnormal Fluctuations in Stock Trading
June 30, 2026
Announcement on Changing Registered Capital, Amending the Articles of Association, and Handling Industrial and Commercial Change Registration
June 24, 2026
Announcement on Actual Controller Being Released on Bail Pending Trial
June 18, 2026
Announcement on Shareholding Reduction Plan for Shareholders
June 12, 2026
Announcement on Voluntary Disclosure on the Acceptance of New Drug Application for BGM0504 Injection for Weight Loss Indication
June 11, 2026
Announcement on Adjusting the Total Cash Dividends for the 2025 Annual Profit Distribution
June 2, 2026
Announcement on Resignation of Directors and Secretary of the Board of Directors
May 26, 2026
Announcement on Redemption Results of "BrightGene Convertible Bonds" and Share Changes
May 22, 2026
The Last Indicative Announcement on the Redemption and Delisting of "BrightGene Convertible Bonds"
May 20, 2026
The 8th Indicative Announcement on the Redemption and Delisting of "BrightGene Convertible Bonds"
May 19, 2026
Announcement on Convening the Q1 2026 Performance Briefing
May 18, 2026
The 6th Indicative Announcement on the Redemption and Delisting of "BrightGene Convertible Bonds"
May 15, 2026
The 5th Indicative Announcement on the Redemption and Delisting of "BrightGene Convertible Bonds"
May 14, 2026
The 4th Indicative Announcement on the Redemption and Delisting of "BrightGene Convertible Bonds"
May 13, 2026
The 3rd Indicative Announcement on the Redemption and Delisting of "BrightGene Convertible Bonds"
May 12, 2026
The 2nd Indicative Announcement on the Redemption and Delisting of "BrightGene Convertible Bonds"
May 11, 2026
Indicative Announcement on Passive Dilution of Shareholding Ratio of Controlling Shareholders, Actual Controllers and Persons Acting in Concert by Reaching 1% Scale
May 10, 2026
The 1st Indicative Announcement on the Redemption and Delisting of "BrightGene Convertible Bonds"
May 8, 2026
Announcement on Redemption and Delisting of "BrightGene Convertible Bonds"
May 7, 2026
19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities
May 6, 2026
BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints
May 5, 2026
Report for Q1 2026
April 29, 2026
Announcement on Redeeming "BrightGene Convertible Bonds" in Advance
April 27, 2026
Indicative Announcement on ""Brightgene Convertible Bonds"" Expected to Meet Conditions for Redemption
April 20, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 10, 2026
Announcement on Adding Provisional Proposal at 2025 Annual General Meeting
April 1, 2026
Announcement on Resignation of the Directors and Senior Management Members
March 30, 2026
BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States
March 25, 2026
Announcement on Convening the 2025 Annual Performance Briefing
March 24, 2026
2025 Annual Report
March 19, 2026
Announcement on Outward Investment and Related Party Transactions
March 10, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Voluntary Disclosure of the Proposed Selection of Partial Products in the National Continuation Drug Procurement
February 11, 2026
Earnings Preannouncement for 2025
January 30, 2026
Announcement on Not Redeeming ""BrightGene Convertible Bonds"" in Advance
January 5, 2026
Announcement on Postponing Investment Projects Financed by Raised Funds
December 30, 2025
Announcement on Interest Payment for "BrightGene Convertible Bonds" in 2025
December 25, 2025
Announcement on Implementation Result of Shares Repurchase and Share Changes
December 15, 2025
Announcement on Progress in Repurchasing Shares
December 1, 2025